Background: Prostate diseases are common in males worldwide with high morbidity.
Gene therapy is an attractive therapeutic strategy for prostate diseases, however, it is currently underdeveloped. As well known, adeno virus (Ad) is the most widely used gene therapy vector. The aims of this study are to explore transduction efficiency of Ad in prostate cancer cells and normal prostate tissue, thus further providing guidance for future prostate pathophysiological studies and therapeutic development of prostate diseases. Prostate is an exocrine gland that is crucial to constituting the male reproductive system, and the functions of prostate are similar in the majority of mammals despite anatomical differences. 1 Three types of prostate diseases are the major threats for the health of prostate, ie, prostatitis, benign prostate hyperplasia (BPH), and prostate cancer. Together, these prostate diseases are severely compromising the life quality and life span of males, especially for the aged male population. For example, BPH is one of the top ten most costly diseases among male populations over 50-year old in the USA, 2 and prostate cancer is the second most diagnosed malignancy and the fifth leading cause for mortality of all cancers in males worldwide. 3, 4 To date, many efforts have been made to prevent or to treat prostate diseases, including surgery, 5 medication, 6 and radiotherapy. . Two days later, EGFP intensity was measured using a fluorescence plate reader (Synergy HT, BioTek, Winooski VT), and further analyzed by flow cytometry as described below.
| Flow cytometry
In total, 10,000 cells from each well were analyzed for EGFP fluorescence signal on a flow cytometer (Guava EasyCyte HT, EMD Millipore, Billerica, MA). Naïve cells were used for gating control.
Data were analyzed by the Flowjo software (FLOWJO, Ashland, OR). (Fig.1A,B ) and the percentage of EGFP-positive cells (Fig. 1C) , respectively. The data showed that Ad transduced TRAMP-C2 cells consistently better than PC3 cells with MOI ranging from 1 to 10 5 (Fig. 1B,C) . Taken together, Ad could also determined using ddPCR (Fig. 2C) . These findings suggested that
| Intratumoral injection and intraprostate injection
Ad could be used to effectively deliver genes of interest to prostate tumor in vivo.
| Ad efficiently transduce mouse prostate in vivo following intraprostate injection
To study the transduction efficiency of Ad in normal prostate tissue, we directly injected Ad vectors into mouse prostate ( Supplementary   Fig. S1 ). The mouse prostate is divided into two lobes of AP and DLP ( Supplementary Fig. S1 ), thus we injected Ad vectors into four sites per prostate, namely the two lobes of AP and two sites of DLP ( Supplementary Fig. S1 ). Prostates were harvested 3 days post injection, AP and DLP cryo-sections were subjected to fluorescence microscopy. We found that Ad could efficiently transduce AP and DLP (Fig. 3A) . Moreover, the genome copy number and the EGFP mRNA levels were determined by ddPCR (Fig. 3B,C) . These results suggested that Ad could be an efficient viral tool for transient gene delivery to mouse prostate in vivo.
| Ad efficiently transduce mouse prostate cells in vivo
To further characterize the prostatic cell types that were transduced with Ad, we performed immunofluorescence staining of mouse AP and DLP sections with antibodies against cellular markers of major prostate cell types including luminal cells (K8), basal cells (K5), and stromal cells (α-actin for smooth muscle cells). We found that Ad was able to transduce the majority of the three cell types in both AP and DLP.
Representative fluorescence microscopic images are shown in Fig. 4 .
These findings indicated that mouse prostate cells could be comprehensively transduced by Ad in vivo.
| DISCUSSION
As the most commonly used viral vector, the advantages of Ad, including large cargo capacity, high efficiency of transduction, and 
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